|
|
*APSFA's Favorites
|
|
**APS
Foundation of America, Inc |
|
|
Founded in June 2005, the APS Foundation
of America, Inc. is dedicated to fostering and facilitating
joint efforts in the areas of education, support, research,
patient services and public awareness of Antiphospholipid
Antibody Syndrome in an effective and ethical manner. |
| |
|
**APS
Friends & Support Forum |
|
|
A forum run by Heidi & Tina founders of
the APS Foundation of America, Inc., a non profit
organization. This forum is an information source and a
friendly support group for people who have Antiphospholipid
Antibody Syndrome or for anyone who's lives are touched by
it. It is sometimes referred to as APS, APLS, or APLA and is
known as Hughes Syndrome or "Sticky Blood" in the UK. APS is
associated with recurrent clotting events including
premature stroke, repeated miscarriages, phlebitis, venous
thrombosis and pulmonary thromboembolism. If this disease
touches your life in some way, please feel free to join in
our discussions! :) We're glad to have you visit! |
| |
|
**GoodSearch.com |
|
|
What if APS Foundation of America - APSFA
earned a penny every time you searched the Internet? Well,
now we can! GoodSearch.com is a new search engine that
donates half its revenue, about a penny per search, to the
charities its users designate. You use it just as you would
any search engine, and it’s powered by Yahoo!, so you get
great results. Just go to http://www.goodsearch.com and be
sure to enter APS Foundation of America - APSFA as the
charity you want to support. Just 500 of us searching four
times a day will raise about $7300 in a year without anyone
spending a dime! And, be sure to spread the word! |
| |
|
*Antiphospholipid Antibody Syndrome (APS) Booklet |
|
|
written by the APS Foundation of America,
Inc. This pamphlet is a layman’s terms summary of
Antiphospholipid Syndrome (APS). It covers such topics as
diagnosis, symptoms, treatment, and coping. It is meant for
patients newly diagnosed, however would also be good for
informing friends and family about your disease. |
| |
|
*Antiphospholipid Antibody Syndrome (APS) Booklet |
|
|
written by the APS Foundation of America,
Inc. |
| |
|
*APS Foundation of America Brochure |
|
|
written by the APS Foundation of America,
Inc. |
| |
|
*Medic Alert |
|
|
HIGHLY recommended! This jewerly could
save your life! |
| |
|
*National Alliance for Thrombosis and Thrombophilia (NATT) |
|
|
The National Alliance for Thrombosis and
Thrombophilia (NATT) is a nationwide, non-profit patient
advocacy group representing the interests of people with
blood clots and clotting disorders, including people with
the APLA syndrome. NATT’s mission is to address major
treatment issues, such as preventing thrombosis and its
complications, and reducing death and illness related to
thrombosis. NATT wants patients to get involved. |
| |
|
Antiphospholipid Antibodies |
|
|
Circulation. 2005;112:e39-e44. © 2005
American Heart Association, Inc. Caron P. Misita, PharmD;
Stephan Moll, MD |
| |
|
Antiphospholipid Antibody Syndrome and Pregnancy |
|
|
Background: Antiphospholipid syndrome
(APS) is a recently recognized autoimmune condition that may
manifest with fetal loss, thrombosis, or autoimmune
thrombocytopenia. Women with these clinical features should
be tested for lupus anticoagulant (LAC) and anticardiolipin
(aCL) antibodies; most patients with APS have both LAC and
aCL immunoglobulin G (IgG) antibodies. The diagnosis of APS
requires the presence of both clinical and biological
features. Systemic lupus erythematosus (SLE) is a chronic
systemic disease with diverse clinical and laboratory
manifestations. LAC (and aCL) predisposes to clotting in
vivo, predominantly by interfering with the antithrombotic
role of phospholipids (PLs); therefore, it is associated
with clinical thrombosis, not bleeding. The antiphospholipid
(aPL) autoantibodies bind moieties on negatively charged PLs
or moieties formed by the interaction of negatively charged
PLs with other lipids, PLs, or proteins. aPL antibodies
belong to the large family of antibodies that react with
negatively charged PLs, including cardiolipin,
phosphatidylglycerol, phosphatidylinositol,
phosphatidylserine, phosphatidylcholine, and phosphatidic
acid. Last Updated: September 4, 2005 |
| |
|
Do you
have Lupus Anticoagulants? |
|
|
The APSFA is currently working with a
company called Precision BioLogic and they are looking for
people who are positive with the Lupus Anticoagulant (LA) to
donate plasma. We are strongly urging people who qualify to
take part in this opportunity as it will only make future
testing more accurate! |
| |
|
eMedicine - Antiphospholipid Antibody Syndrome : Article by
Barry L Myones, MD |
|
|
Last Updated: October 26, 2004 Promtes an
INR in the range of 2.5-3.5. |
| |
|
eMedicine - Antiphospholipid Syndrome : Article by Steven
Carsons, MD |
|
|
Last Updated: December 5, 2004 Based on
the most recent evidence, a reasonable target for the
international normalized ratio (INR) is 2.6-3 for a minimum
of 6 months for a first thrombosis. Patients with recurrent
thrombotic events while well maintained on the above regimen
may require an INR of 3-4 and generally receive
anticoagulation therapy for life. For severe or refractory
cases, a combination of warfarin and aspirin may be used. |
| |
|
FDA Vitamin K List |
|
|
|
| |
|
General Management of the Patient with a Positive
Antiphospholipid Antibody Test: What Evidence Is Available
For You and Your Physician To Consider? |
|
|
Written by: Gale A McCarty, MD, FACP,
FACR You are an individual and your particular case may
involve some features that separate you from the study
patients. What is most likely to have the right balance of
“helpful vs. harmful” effects on you is the major concern of
your physician to prevent the effects of aPL antibodies in
contributing to blood clots and cell or organ damage in you.
Let’s look at the major approaches used to manage your
positive aPL test. |
| |
|
General Management of Thromboses (Blood Clot) II—What
Evidence is Available For You and Your Physician To
Consider? |
|
|
Written by: Gale McCarty, MD, FACP, FACR.
As always, the physician treating the individual APS patient
has to balance the wisdom of these guidelines (which are
general guidelines and not mandates applicable to ALL
patients) with the needs of his/her patient to find the best
answer. |
| |
|
HYDROXYCHLOROQUINE - EVERYTHING OLD IS NEW AGAIN! |
|
|
By: Gale McCarty, MD, FACR, FACP.
Hydroxychloroquine (HCQ, or its trade name-Plaquenil) has a
long and honored history of use in systemic lupus
erythematosus (SLE) as a general medication to decrease
activity of the immune system and decrease symptoms. For
years it has been approved for use by the FDA for lupus and
rheumatoid arthritis, and has been used most frequently for
skin and joint manifestations. It is considered a mainstay
of therapy for any patient with SLE by many lupus experts
and rheumatologists. It has many mechanisms of action, some
related to decrease in the activity of the immune system,
and some related to effects on blood clotting mechanisms.
HCQ belongs to the class of drugs call anti-malarials, which
includes Chloroquine and Atabrine. (This does not mean that
anyone thinks that SLE or APS is caused by the agent that
causes malaria-like most discoveries in medicine, it was the
chance observation that patients with some autoimmune
diseases who got anti-malarial drugs to prevent malaria when
traveling to likely areas of infection noted their symptoms
improved on HCQ). One of the most complete and excellent
reviews of all the literature on the anti-malarials to which
all patients and their physicians are directed is Dr. Dan
Wallace’s Chapter 59 in the Wallace-Hahn Dubois’ Lupus
Erythematosus textbook. Another excellent review on APS
therapy in general has been published by Dr. Robert Roubey. |
| |
|
I Have the Lupus Anticoagulant, But I Don’t Have Lupus? |
|
|
By: Thomas L. Ortel, MD, PhD “...although
the ‘lupus’ anticoagulant was first described in several
patients with lupus, most patients with lupus anticoagulants
actually don’t have any of the other clinical manifestations
of lupus." |
| |
|
Listen to the Patient — Anticoagulation Is Critical in the
Antiphospholipid (Hughes) Syndrome |
|
|
© 2003. The Journal of Rheumatology
Publishing Company Limited. Promotes an INR of greater than
3.0. |
| |
|
Lupus Anticoagulant: Testing While on Anticoagulant Therapy:
Can It Be Done? |
|
|
Written by: Thomas L Ortel, MD, PhD. In
conclusion, it is optimal to test for a lupus anticoagulant
when the patient is on no anticoagulant therapy. All of the
test results can be interpreted more easily in that setting.
Sometimes this can be difficult to arrange, however, and
testing needs to be performed while the patient is still
taking anticoagulants. In this situation, the doctor needs
to work carefully with the laboratory, to understand how the
tests are being performed and to make sure that the results
are interpreted correctly. |
| |
|
Medical Progress- Antiphospholipid Antibody Syndrome |
|
|
PDF File from the New England Journal of
Medicine |
| |
|
Migraine, memory loss, and "multiple sclerosis ".
Neurological features of the antiphospholipid (Hughes’)
syndrome |
|
|
Postgraduate Medical Journal
2003;79:81-83 © 2003 Fellowship of Postgraduate Medicine.
Promotes an INR of greater than 3.0. |
| |
|
Monitoring Warfarin Therapy in Patients with Lupus
Anticoagulants |
|
|
Recommended therapeutic international
normalized ratios (INRs) for oral anticoagulation in
patients with lupus anticoagulants who sustain a
thromboembolic event are controversial. Patients with lupus
anticoagulants often have a prolonged prothrombin time,
which may complicate management of anticoagulant therapy. |
| |
|
New subsets of the antiphospholipid syndrome in 2006:
"PRE-APS" (probable APS) and microangiopathic
antiphospholipid syndromes ("MAPS"). |
|
|
Autoimmun Rev, December 1, 2006; 6(2):
76-80. The concept of "probable" antiphospholipid syndrome
(APS) is almost identical with several conditions which may
presage the development of the APS with its major
complications of large vessel thromboses resulting in deep
vein occlusions in the lower limbs (DVT) particularly and
strokes. These conditions comprising livedo reticularis,
chorea, thrombocytopenia, fetal loss and valve lesions.
These conditions, comprising livedo reticularis, chorea,
thrombocytopenia, fetal loss and valve lesions may be
followed, often years later by diagnosable APS. The issue
whether these patients should be more aggressively treated
on presentation in order to prevent the thrombotic
complications. A new subset of the APS is proposed viz.
microangiopathic antiphospholipid syndrome ("MAPS")
comprising those patients presenting with thrombotic
microangiopathy and demonstrable antiphospholipid antibodies
who may share common although not identical provoking
factors (e.g. infections, drugs), clinical manifestations
and haematological manifestations (severe thrombocytopenia,
hemolytic anaemia) and treatments viz. plasma exchange.
Patients without large vessel occlusions may be included in
the MAPS subset. These conditions include thrombotic
thrombocytopenic purpura (TTP), hemolytic-uremic syndrome
(HUS), and the HELLP syndrome. Patients with catastrophic
antiphospholipid syndrome (CAPS) who do not demonstrate
large vessel occlusions also fall into this group.
Disseminated intravascular coagulation (DIC) has also been
reported with demonstrable antiphospholipid antibodies and
also manifests severe thrombocytopenia and small vessel
occlusions. It may cause problems in differential diagnosis. |
| |
|
Predicting Thrombosis Risk in Individuals with
Antiphospholipid Antibodies |
|
|
Written by: Thomas L Ortel, MD, PhD
“...several studies have shown that the presence of a lupus
anticoagulant in the blood is associated with a higher risk
for a clot than the presence of an anticardiolipin
antibody." |
| |
|
Rare Diseases Clinical Research Network |
|
|
The Rare Diseases Clinical Research
Network was created to facilitate collaboration among
experts in many different types of rare diseases. Our goal
is to contribute to the research and treatment of rare
diseases by working together to identify biomarkers for
disease risk, disease severity and activity, and clinical
outcome, while also encouraging development of new
approaches to diagnosis, prevention, and treatment. |
| |
|
Rare Thrombotic Diseases Consortium (RTDC) |
|
|
The Rare Thrombotic Diseases Consortium
(RTDC) is an integrated group of academic medical centers,
patient support organizations, and clinical research
resources dedicated to conducting clinical research in
different forms of and improving the care of patients with
thrombotic diseases. Funded by the National Institutes of
Health (NIH), the RTDC is part of the Rare Diseases Clinical
Research Network. The operations of the RTDC are directed
from Duke University. Other primary RTDC study sites include
the University of North Carolina, University of Wisconsin,
Centers for Disease Control and Prevention, and the Mayo
Clinic. |
| |
|
Sapporo Criteria for Diagnosing APLA Syndrome |
|
|
|
| |
|
SERONEGATIVE ANTIPHOSPHOLIPID ANTIBODY SYNDROME (SNAPS)…AND
SNAPPING TO IT!! |
|
|
By: Gale McCarty, MD, FACR, FACP. “You
don’t have the syndrome because your tests are low level or
negative…” or “You have livedo, a heart valve problem, and
thrombocytopenia, but these aren’t listed as criteria for
diagnosis” are comments made frequently by healthcare
providers from many specialties to patients with clinical
features suggesting the Antiphospholipid Antibody Syndrome
(APS). |
| |
|
Surgical Management of the Primary Dental Patient on
Warfarin |
|
|
Written to inform Dentists about treating
Warfarin Patients |
| |
|
Thrombosis and the Antiphospholipid Syndrome |
|
|
Hematology 2005 © 2005 The American
Society of Hematology. Summary: Even with the most complete
datasets, it is still important for the physician to develop
a therapeutic plan appropriate for the individual patient,
based on clinical presentation, co-morbid conditions, and
other variables. With uncommon disorders and limited
datasets, such as with the antiphospholipid syndrome,
decision-making becomes even more difficult. Table 3
presents a strategy that the author uses when evaluating and
developing a treatment plan for a patient with
antiphospholipid syndrome and thrombosis, based on the
available studies summarized in this article. Critical areas
for future research include identifying which patients with
antiphospholipid antibodies are at highest risk for
thrombotic complications, developing new antithrombotic
agents that are effective and safe, and investigating novel
approaches to eliminate the autoantibody and, hopefully, the
increased prothrombotic state. |
| |
|
Thrombosis Interest Group of Canada |
|
|
The Thrombosis Interest Group of Canada
consists of a group of 40 specialists in fields related to
thrombosis who collaborate to write evidence-based or
consensus-based clinical guides on the investigation,
management, and diagnosis of thrombotic disorders. |
| |
|
Warfarin in Antiphospholipid Syndrome — Time to Explore New
Horizons |
|
|
The Journal of Rheumatology Feb. 2005
Promotes an INR greater than 3.0. |
| |
|
What is “Micro-Clotting”? |
|
|
By: Thomas L. Ortel, MD, PhD Simply put,
micro-clotting, better referred to as “microvascular
thrombosis”’ describes blood clotting that is occurring in
some of the smallest blood vessels in the body. |
| |
|
Top of Page |
|
|
*In the News & Community - APSFA
|
|
American Stroke Association: Stroke Connection Magazine,
November/December 2006, Page 44 |
|
|
|
| |
|
Antiphospho....what?! |
|
|
The APS Foundation of America, Inc. is
the only United States nonprofit health agency dedicated to
bringing national awareness to Antiphospholipid Antibody
Syndrome (APS), the major cause of multiple miscarriages,
thrombosis, young strokes and heart attacks. We are a
volunteer run, community based 501(c)3 non-profit Public
Charity organization and is dedicated to fostering and
facilitating joint efforts in the areas of education,
support, public awareness, research and patient services. |
| |
|
Antiphospholipid Antibody Syndrome (APS) Sufferers Start
Non-profit Health Agency: Announcing the APS Foundation of
America official website www.apsfa.org |
|
|
Press Release - October 27, 2007 on PRWEB |
| |
|
Antiphospholipid Antibody Syndrome Awareness Month |
|
|
Michigan Proclamation for 2007 |
| |
|
APS Awareness PSA |
|
|
|
| |
|
APS Awareness PSA for WFLS |
|
|
PSA airing on 93.3 WFLS- Real Country
Variety, Fredericksburg, VA |
| |
|
APS Awareness Starts Here |
|
|
Written by: Charles Strickler. What is
APS? How do we increase awareness of APS? What research
needs to be done to improve treatment options? These were
some of the many questions discussed at the awareness and
fundraising dinner that was hosted by me, my wife, Mary
Strickler and our co-hosts, David and Kim Penberthy. We held
the dinner May 17th, and it seemed more than appropriate to
have such an event just prior to APS Awareness Month in
June! |
| |
|
APS FOUNDATION OF AMERICA, INC. JOINS WITH NORD TO CELEBRATE
THE 25th ANNIVERSARY OF THE ORPHAN DRUG ACT |
|
|
APSFA Press Release - January 2008 |
| |
|
APS in the Community |
|
|
On April 22nd the APSFA made an
appearance at the annual March of Dimes WalkAmerica event in
Springfield, Virginia. |
| |
|
APS is a snake in the grass and can bite or kill without
warning |
|
|
APSFA Press Release - Week 4 - 2007 |
| |
|
APS Linked to Birth Difficulties |
|
|
APSFA Press Release - Week 2 - 2007 |
| |
|
APSFA To the Rescue |
|
|
Written by: Seren Estrada Thanks to the
support of the APSFA, I expect to continue my education with
the help of the DSSO. It also goes to show that the APS
Foundation of America, Inc is truly dedicated to advocating
for people with APS. |
| |
|
Eau Claire, Leader-Telegram, November 29, 2006, Page 1C |
|
|
|
| |
|
Grand Rounds at Marshfield Clinic |
|
|
written by Tina Pohlman |
| |
|
June is APS Awareness Month PSA |
|
|
June is Antiphospholipid Antibody
Syndrome (APS) Awareness month. |
| |
|
June is APS Awareness Month ~ Get In the Flow! |
|
|
Written by: Tina Pohlman |
| |
|
June is APS Awareness Month: Get in the Flow! |
|
|
The APS Foundation of America, Inc.
(APSFA) has declared June as National Antiphospholipid
Antibody (APS) Awareness Month. We are educating the public
and medical community about this disorder, urging people to
Get in the Flow! |
| |
|
JUNE IS APS AWARENESS MONTH: GET IN THE FLOW! |
|
|
APSFA Press Release - Week 1 - 2007 |
| |
|
Lupus Foundation of America: Pacific Northwest Chapter: In
the Lupe! December 2006, Page 5 |
|
|
|
| |
|
Lupus Foundation of Ontario: Lupus Talk, October 2006 to
December 2006, page 5 |
|
|
|
| |
|
MO-KAN Spreads APS Awareness |
|
|
Written by Dana Stuart. “Mo-Kan” is a
phrase commonly used in the Missouri-Kansas region to
describe various missions or goals that Missouri and Kansas
businesses and residents CAN accomplish together. Frequently
used for public service announcements, advertisements, and
other miscellaneous uses, “Mo-Kan” has become the unofficial
slogan for several alliances, which have formed for some
very worthy causes. Now “Mo-Kan” spreads APS Awareness! |
| |
|
One Fine Day |
|
|
Written by: Dana Stuart |
| |
|
Our Journey with Mystery Diagnosis |
|
|
written by Michelle LaRue |
| |
|
Proclamation 2007 - State of CT |
|
|
Thank you for your support! |
| |
|
Proclamation 2007 - State of KY |
|
|
Thank you for your support! |
| |
|
Proclamation 2007 - State of MO |
|
|
Thank you for your support! |
| |
|
Proclamation 2007 - State of OH |
|
|
Thank you for your support! |
| |
|
Proclamation 2007 - State of PA |
|
|
Thank you for your support! |
| |
|
Proclamation 2007 - State of WI |
|
|
Thank you for your support! |
| |
|
Quarterly Newsletter "Antiphospho....What?" |
|
|
Volume 6 - Summer 2007. written by the
APS Foundation of America, Inc. |
| |
|
Quarterly Newsletter "Antiphospho....What?" |
|
|
Volume 2 - Summer 2006. written by the
APS Foundation of America, Inc. |
| |
|
Quarterly Newsletter "Antiphospho....What?" |
|
|
Volume 1 - Spring 2006. written by the
APS Foundation of America, Inc. |
| |
|
Quarterly Newsletter "Antiphospho....What?" |
|
|
Volume 5 - Spring 2007. written by the
APS Foundation of America, Inc. |
| |
|
Quarterly Newsletter "Antiphospho....What?" |
|
|
Volume 3 - Fall 2006. written by the APS
Foundation of America, Inc. |
| |
|
Quarterly Newsletter "Antiphospho....What?" |
|
|
Volume 4 - Fall 2006. written by the APS
Foundation of America, Inc. |
| |
|
Quarterly Newsletter "Antiphospho....What?" |
|
|
Volume 7 - Fall 2007. written by the APS
Foundation of America, Inc. |
| |
|
Quarterly Newsletter "Antiphospho....What?" |
|
|
Volume 8 - Winter/Spring 2008. written by
the APS Foundation of America, Inc. |
| |
|
Quarterly Newsletter "Antiphospho....What?" |
|
|
Volume 9 - Spring/Summer 2008. Written by
the APS Foundation of America, Inc. |
| |
|
Rare condition often overlooked |
|
|
By Shannon Farr, Saturday, June 30, 2007 |
| |
|
Rare disorder's diagnosis draws media attention |
|
|
Published: Sunday, November 20, 2005
12:03 AM CST. A Ventura teen’s struggle to obtain a
diagnosis for a relatively rare auto-immune disorder will be
featured on the Discovery Health Channel. Angie Abbas, 18,
who has Antiphospholipid Antibody Syndrome (APS), will be
featured in a segment of “Mystery Diagnosis” in early 2006.
The date has not been determined. Angie’s diagnosis was
difficult because APS mimics other disorders, LaRue said. In
addition, Angie’s primary symptom, a severe twitching of the
head and neck, is not typical. In the meantime, producers of
“Mystery Diagnosis” had learned about Angie through the APS
Foundation of America, a relatively new organization in
which Angie and her mother had become active. |
| |
|
Sisters' ailment identified |
|
|
07/23/2007 - By Christy Murdoch , For the
Herald-Standard |
| |
|
Strokes and heart attacks could be caused by APS |
|
|
APSFA Press Release - Week 3 - 2007 |
| |
|
Thrombosis Education Days ~ MI & Chicago |
|
|
written by Heidi Ponagai. The National
Alliance of Thrombosis and Thrombophilia (NATT) and the MSU
Center for Bleeding and Clotting Disorders held an education
day on March 24th in Lansing, Michigan for people who have
had blood clots, who have clotting disorders, and their
families and friends. We were fortunate enough to get a
booth at the seminar to display and distribute APSFA
brochures and booklets to people. |
| |
|
Ventura teen on ‘Mystery Diagnosis’ on March 6 |
|
|
VENTURA — A program featuring a Ventura
teen’s struggle to obtain a diagnosis for a relatively rare
auto-immune disorder will be aired March 6 on the Discovery
Health Channel, the show’s producers have announced. Angie
Abbas, 18, who has Antiphospholipid Antibody Syndrome (APS),
will be featured at 9 p.m. Central Standard Time on March 6.
“Mystery Diagnosis” is a series that tells the stories of
how real people have obtained difficult diagnoses. It is
produced through True Entertainment LLC of New York City.
The program was filmed in October at a Minneapolis
production studio, Mercy Medical Center-North Iowa in Mason
City and Angie’s home in rural Ventura. The Discovery Health
Channel is Channel 203 on Mediacom’s digital-plus package or
Channel 93 through CL Tel. |
| |
|
WFLS 93.3 APSFA Air Check - Sample 1 |
|
|
These are air checks that are currently
hitting the DC Metro Area. About 1 million listeners at any
given time. |
| |
|
WFLS 93.3 APSFA Air Check - Sample 2 |
|
|
These are air checks that are currently
hitting the DC Metro Area. About 1 million listeners at any
given time. |
| |
|
WFLS 93.3 APSFA Air Check - Sample 3 |
|
|
These are air checks that are currently
hitting the DC Metro Area. About 1 million listeners at any
given time. |
| |
|
Top of Page |
|
|
APS - *General
|
|
*Antiphospholipid Antibody Syndrome |
|
|
Last Updated: October 26, 2004 Author:
Barry L Myones, MD, Director of Research, Pediatric
Rheumatology Center, Texas Children's Hospital at Houston;
Associate Professor, Departments of Pediatrics & Immunology,
Pediatric Rheumatology Section, Baylor College of Medicine
Coauthor(s): Deborah McCurdy, MD, Director of Rheumatology,
Department of Pediatric Rheumatology, Children's Hospital of
Orange County Barry L Myones, MD, is a member of the
following medical societies: American Academy of Pediatrics,
American Association for the Advancement of Science,
American Association of Immunologists, American College of
Rheumatology, American Heart Association, American Society
for Microbiology, Clinical Immunology Society, and Texas
Medical Association Editor(s): Terry Chin, MD,
Allergy/Immunology/Pulmonology; Co-Director Cystic Fibrosis
and Home Ven, Associate Professor of Pediatrics, Department
of Pediatrics, Loma Linda University and Children's
Hospital; Mary L Windle, PharmD, Adjunct Assistant
Professor, University of Nebraska Medical Center College of
Pharmacy; David D Sherry, MD, Professor of Pediatrics,
University of Pennsylvania; Director of Clinical
Rheumatology, Division of Rheumatology, Children's Hospital
of Philadelphia; Daniel Rauch, MD, Director, Pediatric
Hospitalist Program, Associate Professor, Department of
Pediatrics, New York University School of Medicine; and
Norman T Ilowite, MD, Chief, Division of Rheumatology,
Schneider Children's Hospital; Professor, Department of
Pediatrics, Albert Einstein College of Medicine |
| |
|
*Antiphospholipid Antibody Syndrome (APS) Booklet |
|
|
written by the APS Foundation of America,
Inc. This pamphlet is a layman’s terms summary of
Antiphospholipid Syndrome (APS). It covers such topics as
diagnosis, symptoms, treatment, and coping. It is meant for
patients newly diagnosed, however would also be good for
informing friends and family about your disease. |
| |
|
*Antiphospholipid Antibody Syndrome (APS) Booklet |
|
|
written by the APS Foundation of America,
Inc. |
| |
|
*Antiphospholipid Syndrome (APS) |
|
|
Written by: Jan M. Pankey, M.D.
Children’s Hospital & Research Center Oakland, California
for the National Alliance for Thrombosis and Thrombophilia
(NATT) |
| |
|
*APS & Surgery Brochure |
|
|
written by the Hospital for Special
Surgery |
| |
|
*APS & You |
|
|
written by the APS Foundation of America,
Inc. This pamphlet is a layman’s terms summary of
Antiphospholipid Syndrome (APS). It covers such topics as
diagnosis, symptoms, treatment, and coping. It is meant for
patients newly diagnosed, however would also be good for
informing friends and family about your disease. |
| |
|
*APS Information Brochure |
|
|
written by the Hospital for Special
Surgery. |
| |
|
*Current News Articles Dealing with APS & Related Problems |
|
|
This link contains full news articles and
many up to date medical journal abstracts dealing with APS
and its related diseases. Free Registration is required. |
| |
|
*The Antiphospholipid Syndrome |
|
|
written by Dr. Yaniv & Professor Yehuda
Shoenfeld. Copyright 2004. Redistributed with permission
from authors. |
| |
|
*What is Antiphospholipid Antibody Syndrome? |
|
|
written by the Rare Thrombotic Disease
Consortium. Redistributed with permission from the authors. |
| |
|
*Women & APS |
|
|
written by the APS Foundation of America,
Inc. |
| |
|
A Patients Guide to APS |
|
|
Doctor Hughes Book on a website |
| |
|
About thrombosis: thrombophilia: acquired thrombophilia: APS |
|
|
Another article that supports an INR of
3.0 to 4.0 for APS patients. |
| |
|
American Venous Forum - Patients Section |
|
|
Founded in 1988, the American Venous
Forum provides a serious academic colloquium to physicians
interested in the research, education, and clinical
investigation in the field of venous diseases. The Forum
membership includes more than 225 board-certified vascular
surgeons who have an accomplished record of interest and
contribution to the management of venous disease. The
mission of the American Venous Forum is to improve the care
of patients with venous and lymphatic disorders by providing
a forum dedicated to education and to the exchange of
information concerning basic and clinical research
pertaining to the venous and lymphatic systems. In past
years, the Forum has dedicated itself to academic pursuits
through vigorous educational meetings throughout the
country. Today, the Forum is a diverse organization that
includes a directory of experienced investigators and
clinicians, several of whom can also speak or assist in
research on a variety of venous-related topics. The Forum
also offers guidelines and protocols for the development of
research and clinical trials. With the guidance of the AVF
governing officers, the AVF will continue to bring medical
professionals and patients the latest venous health
information. The AVF By-Laws include more information on our
objectives, committees, meetings, and dues. |
| |
|
Anti-phospholipid antibody syndrome |
|
|
The MayoFoundation for Medical Education
and Research provides the following web link addressing
antiphospholipid syndrome. |
| |
|
Anticardiolipin Test and the Antiphospholipid (Hughes)
Syndrome: 20 Years and Counting! |
|
|
© 2004. The Journal of Rheumatology
Publishing Company Limited. |
| |
|
ANTIPHOSPHOLIPID ANTIBODIES |
|
|
by Dr. Ron Ascherson |
| |
|
ANTIPHOSPHOLIPID ANTIBODY SYNDROME |
|
|
(APS) is a term used to describe the
association between recurrent clinical events such as
thrombosis (arterial or venous), thrombocytopenia, or fetal
loss and the presence of a persistent antiphospholipid
antibody 1-3. Other clinical conditions associated with the
syndrome include stroke, transient ischemic attack, livedo
reticularis, migraine, epilepsy, and heart valve disease4.
The syndrome is termed "primary" if there is no accompanying
autoimmune disease and "secondary" if the patient also has
systemic lupus erythematosus (SLE) or an autoimmune
disorder1,2,5. Certain infectious diseases and drugs may
also result in the formation of antiphospholipid antibodies
which do not appear to be associated with clinical
complications and do not require therapy1,3,5. |
| |
|
Antiphospholipid Antibody Syndrome |
|
|
Indian Pediatrics 2001; 38: 1413-1416
Promotes an INR greater than 3. |
| |
|
Antiphospholipid Antibody Syndrome |
|
|
Antiphospholipid syndrome (APS) is
characterized by the following: venous or arterial
thrombosis--a condition where clots, called thrombi, form in
the blood vessels; recurrent miscarriages--the repeated loss
of the fetus in pregnancies; and thrombocytopenia--a low
number of blood platelets that can lead to bleeding, seen as
bruising and tiny red dots on the skin. Medical College of
Wisconsin. |
| |
|
Antiphospholipid Antibody Syndrome |
|
|
Intelihealth Website |
| |
|
Antiphospholipid Antibody Syndrome (APS) |
|
|
Neuroland |
| |
|
Antiphospholipid Antibody Syndromes (APS) |
|
|
from the Rare Thrombotic Diseases
Consortium |
| |
|
Antiphospholipid or Hughes' syndrome |
|
|
Supports an INR of 3.0 to 4.0 for APS
patients. |
| |
|
Antiphospholipid Syndrome |
|
|
*Summary Points Antiphospholipid syndrome
is characterized by the presence of venous and/or arterial
thrombosis and/or pregnancy morbidity and the presence of
antiphospholipid antibodies. Long-term anticoagulation is
recommended for antiphospholipid syndrome patients with
recurrent vascular events. For antiphospholipid syndrome
patients with recurrent pregnancy events, aspirin plus
heparin is recommended during pregnacy. Promotes an INR of
>3. |
| |
|
Antiphospholipid Syndrome |
|
|
Antiphospholipid syndrome (APS) is
characterized by the following: venous or arterial
thrombosis--a condition where clots, called thrombi, form in
the blood vessels; recurrent miscarriages--the repeated loss
of the fetus in pregnancies; and thrombocytopenia--a low
number of blood platelets that can lead to bleeding, seen as
bruising and tiny red dots on the skin. |
| |
|
Antiphospholipid syndrome |
|
|
The antiphospholipid syndrome (APS) is
characterized by venous and/or arterial thrombosis,
recurrent pregnancy loss and the presence of
antiphospholipid antibodies. The antiphospholipid antibodies
(anticardiolipin, anti-bêta2GPI antibodies, lupus
anticoagulant) interacting with various coagulation
proteins, platelets or endothelial cells may contribute to
disease pathogenesis. Incidence remains unknown, however the
reported prevalence of antiphospholipid antibodies in the
general population is low (1-4.5%) and increases with age.
The main clinical manifestations associated with APS are
thromboses, pregnancy morbidity, thrombocytopenia,
neurological symptoms, livedo reticularis, hemolytic anemia.
The antiphospholipid antibodies have been detected in
approximately 1/3 of the patients with systemic lupus
erythematosus (SLE). High anticardiolipin antibodies titers,
lupus anticoagulant and especially anti-bêta2GPI antibodies
are important predictors of APS clinical manifestations in
SLE patients. The management of thrombosis includes
long-term, high-intensity warfarin therapy [International
Normalized Ratio (INR superior or equal to 3)]. For
pregnancy morbidity the recommended therapy is low-dose
aspirin (80 mg/day) plus subcutaneous unfractionated heparin
or low-molecular-weight heparin. |
| |
|
Antiphospholipid Syndrome |
|
|
Information provided by the UMHS
Hemophilia and Coagulation Disorders Program, February 2003 |
| |
|
Antiphospholipid Syndrome |
|
|
Copyright © 1996-2005 C. Stephen Foster
M.D. All Rights Reserved. |
| |
|
Antiphospholipid Syndrome |
|
|
Last Updated: August 10, 2007 |
| |
|
Antiphospholipid Syndrome |
|
|
Last modified Monday, August 10, 2007 |
| |
|
Antiphospholipid Syndrome |
|
|
Virtual Medical Centre. Modified:
14/7/2006 |
| |
|
Antiphospholipid syndrome |
|
|
An. Bras. Dermatol. vol.80 no.3 Rio de
Janeiro May/June 2005. Antiphospholipid syndrome is an
acquired multisystem disorder characterized by recurrent
thromboses in the arterial system, venous system, or both.
Antiphospholipid syndrome is classified into 2 groups:
primary and secondary. Secondary antiphospholipid syndrome
is often associated with systemic lupus erythematosus and
less frequently with infections, drugs and other diseases.
Serologic markers are antiphospholipid antibodies, lupus
anticoagulant and anticardiolipin. The primary diagnostic
criteria include arterial thrombosis or venous thrombosis
and recurrent fetal loss. About 41% of patients with lupus
anticoagulant have skin lesions as the first sign of
antiphospholipid syndrome. Cutaneous manifestations include
livedo reticularis, cutaneous ulceration and livedo
vasculitis. The mainstays of prophylaxis and treatment of
thrombosis are anticoagulant and antiplatelet agents. |
| |
|
Antiphospholipid Syndrome - Making the Diagnosis |
|
|
SJS - September 2003 Levine JS, Branch
DW, Rauch J. The antiphospholipid syndrome. N Engl J Med.
2002;346(10):752-63. |
| |
|
Antiphospholipid Syndrome from eMedicine |
|
|
Last Updated: December 5, 2004 Author:
Steven Carsons, MD, Chief, Division of Rheumatology,
Allergy, and Immunology, Professor of Medicine, Department
of Internal Medicine, Winthrop University Hospital, State
University of New York at Stony Brook |
| |
|
Antiphospholipid syndrome: an overview |
|
|
CMAJ • June 24, 2003; 168 (13) © 2003
Canadian Medical Association or its licensors |
| |
|
APS Article on Medicine Net |
|
|
Medical Author: William C. Shiel Jr., MD,
FACP, FACR Last Editorial Review: 9/18/2005 |
| |
|
APS Foundation of South Africa |
|
|
APSSA is a foundation formed to promote
much needed awareness of the Antiphospholipid Syndrome (APS)
in South Africa. |
| |
|
Euro-Phospholipid on Line |
|
|
Official Web-site of the "European Forum
on Antiphospholipid Antibodies" |
| |
|
Hughes' Syndrome |
|
|
In 1983 and during the following two
years, the Lupus Research Unit at St Thomas published a
number of papers showing that certain blood proteins
(antiphospholipid antibodies) were associated with a
syndrome of clotting (thrombosis), recurrent miscarriages
and brain disease. Between 1983 and 1985, a comprehensive
clinical/laboratory profile was presented showing, for the
first time, a wide spectrum of clinical features including
the association with artery thrombosis (including major
organs such as kidney and liver), brain disease (strokes and
other features), skin rashes, low platelet counts, epilepsy
and migraine. |
| |
|
Management of Antiphospholipid Antibody Syndrome |
|
|
Lim W, Crowther MA, Eikelboom JW.
Management of antiphospholipid antibody syndrome. A
systematic review. JAMA 2006; 295:1050–1057 |
| |
|
Managing antiphospholipid syndrome |
|
|
Copyright Springhouse Corporation Mar
2004 |
| |
|
Medical Progress- Antiphospholipid Antibody Syndrome |
|
|
PDF File from the New England Journal of
Medicine |
| |
|
New Treatments For Lupus Anticoagulants |
|
|
|
| |
|
NORD - National Organization for Rare Disorders, Inc. |
|
|
Copyright 1994, 1995, 1996, 2001, 2002 |
| |
|
Official Web-site of the "European Forum on Antiphospholipid
Antibodies" |
|
|
|
| |
|
Old-fashioned detective work |
|
|
August 20, 2005 |
| |
|
Pathogenesis of the Antiphospholipid Syndrome |
|
|
|
| |
|
SINDROME da ANTICORPI ANTIFOSFOLIPIDI |
|
|
This page is in Italian. |
| |
|
The "primary" antiphospholipid syndrome: major clinical and
serological features. |
|
|
Medicine (Baltimore). 1989
Nov;68(6):366-74. |
| |
|
The Antiphospholipid Story |
|
|
© 2003. The Journal of Rheumatology
Publishing Company Limited. |
| |
|
The Antiphospholipid Syndrome |
|
|
Most patients with venous or arterial
thrombosis and APS do well with conventional warfarin
treatment (target INR 2.0 - 3.0). It is recommended that
patients with recurrent thrombosis despite conventional
doses of warfarin should maintain an INR of 3.0 - 4.0. This
recommendation is based on one descriptive study and
requires confirmation by randomised trials. The benefit of
adding aspirin in arterial disease is not clear, and is
likely to increase the risk of bleeding. |
| |
|
The Antiphospholipid Syndrome |
|
